Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Invitrogen has introduced its new Predictor hERG fluorescence polarization assay kit that enables better screening for cardiotoxicity traits of potential drug compounds early in the discovery process.
Subscribe to our email newsletter
Invitrogen’s Predictor hERG fluorescence polarization assay kit is said to be the first commercially available non-radioactive, homogenous assay kit for high-throughput screening of compounds interacting with the hERG ion channel.
According to the company, the Predictor hERG assay eliminates radioactivity and allows researchers to rapidly and accurately triage compounds for more detailed patch-clamp analysis. In addition, the Predictor hERG assay results are predictive of patch-clamp data, faster and less expensive than current radioligand displacement tests.
Brian Pollok, chief scientific officer of Invitrogen, said: “The Predictor hERG assay delivers a novel solution that is accurate, efficient and convenient for determining potential hERG liability of compounds.”